TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Olema Pharmaceuticals (NASDAQ: OLMA).The analysts commented, "The SABCS abstract ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE